ANIK Q4 2023 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q4 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$43M+8.5% YoY

Gross Profit

$26M61.3% margin

Operating Income

-$64M-148.4% margin

Net Income

-$63M-146.6% margin

EPS (Diluted)

$-4.30

QoQ Revenue Growth

+3.6%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$2M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$271M

Total Liabilities

$58M

Stockholders' Equity

$212M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43M	$40M	+8.5%
Gross Profit	$26M	$24M	+9.1%
Operating Income	-$64M	-$7M	-856.7%
Net Income	-$63M	-$5M	-1183.6%

Revenue Segments

Joint Preservation and Restoration

$15M85%

Non-Orthopedic

$3M15%

Geographic Segments

UNITED STATES

$32M87%

Europe

$5M13%